NASDAQ · CYTO
Healthcare · Biotechnology
$0.30
Up+$0.30 (+0.00%)
Updated Sep 18, 2026, 5:53 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CYTO does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning CYTO.
CYTO research
Company profile and research snapshot.
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
GlobeNewswire Inc. · Sep 20, 2024
Altamira Therapeutics, a company developing nanoparticle-based technology for RNA delivery, will host a financial results and business update call on September 24, 2024.
GlobeNewswire Inc. · Sep 19, 2024
Altamira Therapeutics, a company focused on RNA delivery technology, announced the closing of a $4 million public offering with the potential for an additional $8 million from the exercise of warrants. The company plans to use the proceeds for working capital and general corporate purposes.
GlobeNewswire Inc. · Sep 17, 2024
Altamira Therapeutics, a company developing RNA delivery technology, announced the pricing of a $4 million public offering with additional potential proceeds of up to $8 million from the exercise of warrants. The offering is expected to close on September 19, 2024, subject to customary closing conditions.
GlobeNewswire Inc. · Sep 3, 2024
Altamira Therapeutics, a company developing RNA delivery technology, announced that its CEO will be presenting at the H.C. Wainwright Global Investment Conference on September 9-11, 2024.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CYTO.
No results
No recent SID articles mention CYTO.
